ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1041 • ACR Convergence 2020

    Pharmaco-epidemiology of Non-infectious Ocular Inflammatory Disease in a Tertiary Academic Center

    Sanjeev Patil1, Justine Cheng2, Lorraine Provencher3 and Scott Vogelgesang4, 1University of Vermont Medical Center, Essex Junction, VT, 2University of Iowa Hospitals and Clinics, Iowa City, IA, 3Cincinnati Eye Institute, Cincinnati, OH, 4University of Iowa Hospitals and Clinics, Iowa City, IA

    Background/Purpose: Non-Infectious Ocular inflammatory disease (OID) is a group of immune-mediated diseases involving the ocular surface, uveal tract, retina, optic nerve, and peri-orbital tissue. Patients…
  • Abstract Number: 1047 • ACR Convergence 2020

    Prospective Analysis of a Cohort of Patients with Interstitial Lung Disease Associated with Connective Tissue Disease and Their Response to Immunosuppression with Mycophenolate Mofetil and Rituximab

    Yan Li1, Hassan Baig2, Carlos Rojas2, Justin Stowell2, Elizabeth Lesser2, Shalmali Borkar2, Andy Abril1 and Isabel Mira-Avendano1, 1Mayo Clinic, Ponte Vedra Beach, FL, 2Mayo Clinic, Jacksonville, FL

    Background/Purpose: Connective tissue diseases (CTDs) are commonly identified causes for interstitial lung disease (ILD). Compared with idiopathic interstitial pneumonias, patients with CTD-ILD and interstitial pneumonia…
  • Abstract Number: 1046 • ACR Convergence 2020

    Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis

    Joe Zhuo1, Qisu Zhang2, Keith Knapp3, Yuexi Wang4, Cynthia Gutierrez4, Ding He4, Lin Xie4, Sonie Lama1 and Gary Craig5, 1Bristol-Myers Squibb Company, Princeton, NJ, 2STATinMED Research (at time of analysis), Ann Arbor, MI, 3Discus Analytics LLC, Spokane, WA, 4STATinMED Research, Ann Arbor, MI, 5Arthritis Northwest, PLLC, Spokane, WA

    Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of RA and is associated with increased morbidity and mortality.1 Previous studies have shown variability in…
  • Abstract Number: 1052 • ACR Convergence 2020

    Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska

    Joanna Marco1 and Elizabeth Ferucci2, 1University of Washington, Seattle, WA, 2Alaska Native Tribal Health Consortium, Anchorage, AK

    Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
  • Abstract Number: 1054 • ACR Convergence 2020

    Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients

    José Luis Martín-Varillas1, Vanesa Calvo-Río2, Lara Sanchez-Bilbao2, Inigo Gonzalez-Mazon3, Ignacio Torre4, Alvaro García Martos5, Amalia Sánchez Andrade6, Angel García Aparicio7, Juan Ramón De dios8, Ana Urriticoechea9, Olga Maiz Alonso10, Raul Veroz11, Andrea García Valle12, Sergio Rodriguez Montero13, Roberto Miguelez14, Vega Jovani15, Marisa Hernandez Garfella16, Arantxa Conesa17, Olga Martinez Gonzalez18, Paula Rubio Muñoz19, Eva Peña Sainz-Pardo20, Miguel Ángel González-Gay21 and Ricardo Blanco2, 1Hospital Sierrallana, Torrelavega, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Basurto, Bilbao, Spain, 5Hospital del Tajo, Madrid, Spain, 6H. Lucus Augusti, Lugo, Spain, 7H. Mostoles, Madrid, Spain, 8H. Alava, Alava, Spain, 9Can Misses, Ibiza, Spain, 10Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 11H. Mérida, Mérida, Spain, 12H. Palencia, Palencia, Spain, 13H. Virgen de Valme, Sevilla, Spain, 14Toledo, Toledo, Spain, 15H. Alicante, Alicante, Spain, 16H. Valencia, Valencia, Spain, 17H. Castellón, Castellón, 18H. Salamanca, Salamanca, 19H. Esperit Sant, Barcelona, Spain, 20H. 12 de Octubre, Madrid, Spain, 21Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis. However, there is not enough evidence for the use…
  • Abstract Number: 1049 • ACR Convergence 2020

    Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern

    Paul Dellaripa1, Martin Aringer2, Anna Maria Hoffmann-Vold3, Clive Kelly4, Shikha Mittoo5, Alexandra James6, Klaus Rohr6, Susanne Stowasser6 and Yoshikazu Inoue7, 1Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, 2Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, 3Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle upon Tyne, United Kingdom, 5University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, 6Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 7Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan, Sakai City, Osaka, Japan

    Background/Purpose: In the INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in patients with…
  • Abstract Number: 1044 • ACR Convergence 2020

    Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center

    Lara Sanchez-Bilbao1, David Martinez-Lopez2, Inigo Gonzalez-Mazon3, Maria José García-García4, Montserrat Rivero-Tirado4, Beatriz Castro4, Javier Crespo4, Miguel Ángel González-Gay5 and Ricardo Blanco1, 1Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Inflammatory bowel disease (IBD), which includes Crohn's disease (CD), and Ulcerative colitis (UC) are related to Spondyloarthritis (SpA). Ocular manifestations (OM) are well-stablished in…
  • Abstract Number: 1057 • ACR Convergence 2020

    Earlier Cancer Diagnosis After Idiopathic Inflammatory Myopathy Onset Is Associated with Improved Long Term Survival – Results from Four European Cohorts

    Alexander Oldroyd1, Paul New2, Janine Lamb1, William Ollier1, Robert Cooper2, Kuberacka Mariampillai3, Olivier Benveniste3, Jiří Vencovský4, Heřman Mann5, Zoltan Griger6, Melinda Nagy-Vincze6, Katalin Dankó6 and Hector Chinoy7, 1University of Manchester, Manchester, United Kingdom, 2University of Liverpool, Liverpool, United Kingdom, 3Sorbonne Université, Paris, France, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 5Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 6University of Debrecen, Debrecen, Hungary, 7The University of Manchester, Manchester, United Kingdom

    Background/Purpose: The idiopathic inflammatory myopathies (IIMs) are strongly associated with the development of clinically detectable cancer. Cancer screening has therefore been advocated in newly diagnosed…
  • Abstract Number: 1060 • ACR Convergence 2020

    B-cell-rich Inflammatory Myopathies in Adults: Striking Association with Connective Tissue Diseases

    Pat Korathanakhun1, Océane Landon-Cardinal2, Valérie Leclair3, Benjamin Ellezam4, Alain Meyer5, Josiane Bourré-Tessier2, Anne-Marie Mansour6, Sandrine Larue7, François Grand'Maison7, Rami Massie8, Matthieu Le Page9, Catherine Isabelle7, Nathalie Routhier6, Flavie Roy10, Minoru Satoh11, Marvin Fritzler12, Jean-Luc Senécal2, Yves Troyanov13, Marie Hudson3, Jason Karamchandani14 and Erin O'Ferrall8, 1Montreal Neurological Institute and Hospital, Montreal, QC, Canada, 2Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 3Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, 4Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada, 5Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 6Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada, 7Hôpital Charles-Lemoyne, Longueuil, QC, Canada, 8Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, 9Centre hospitalier de Lanaudière, Saint-Charles-Borromée, QC, Canada, 10Uiversité de Montréal, Montreal, QC, Canada, 11Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, 12Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 13Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, 14Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada

    Background/Purpose: Myositis with significant B-cell infiltrates on muscle biopsy has scarcely been described in adults. Radke (2018) found B cells in adult dermatomyositis (DM) and…
  • Abstract Number: 1061 • ACR Convergence 2020

    Daily Myositis Symptom Changes Collected via a Smartphone-Based App Are Associated with Flare Occurrence – Providing Evidence of Potential Digital Biomarkers

    Alexander Oldroyd1, Belay Yimer2, Max Little3, William Dixon2 and Hector Chinoy4, 1University of Manchester, Manchester, United Kingdom, 2Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, 3University of Birmingham, Birmingham, United Kingdom, 4The University of Manchester, Manchester, United Kingdom

    Background/Purpose: The concept of idiopathic inflammatory myopathy (IIM) flare is widely used, although no consensus definition exists. Studies have demonstrated the feasibility and utility of…
  • Abstract Number: 1056 • ACR Convergence 2020

    Descriptive Data Analysis of Patients with Anti Jo1 Syndrome (AJS) and Lung Involvement

    Mohamed Alalwani1, Bassam Alhaddad2, Basem Zraik3, Christopher O'Rourke3, Ruchi Yadav3, Ali Askari1, Charles Malemud1 and Soumya Chatterjee4, 1Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, 2MetroHealth Medical Center, Westlake, OH, 3Cleveland Clinic, Cleveland, OH, 4Cleveland Clinic, Richmond Heights, OH

    Background/Purpose: To evaluate the patterns, severity and, prognostic parameters of interstitial lung disease (ILD) in Anti Jo1 Syndrome (AJS).Methods: We identified 51 anti-Jo-1 patients with…
  • Abstract Number: 1067 • ACR Convergence 2020

    Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease

    Takahisa Gono1, Yuka Okazaki1 and Masataka Kuwana2, 1Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan

    Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is associated with interstitial lung disease (ILD), which often represents rapidly progressive course and fatal outcomes. Circulating levels…
  • Abstract Number: 1064 • ACR Convergence 2020

    Anti-SMN Autoantibodies Are Associated with Systemic Sclerosis Small Bowel Involvement in anti-U1RNP Positive Autoimmune Myositis

    Caroline Vo1, Océane Landon-Cardinal2, Alexandra Albert3, Alain Meyer4, Valérie Leclair5, Josiane Bourré-Tessier2, Sabrina Hoa2, Eric Rich1, Jean-Richard Goulet1, Benjamin Ellezam6, Maude Bouchard-Marmen7, Martial Koenig8, Geneviève Gyger5, Ira N. Targoff9, Marie Hudson5, Minoru Satoh10, Marvin Fritzler11, Yves Troyanov12 and Jean-Luc Senécal2, 1Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, 2Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 3Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada, 4Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, 5Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, 6Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada, 7Division of Rheumatology, Centre Hospitalier de l’Université Laval, Department of Medicine, Université Laval, Québec, QC, Canada, 8Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, 9University of Oklahoma Health Sciences Center, Oklahoma City, OK, 10Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, 11Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 12Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada

    Background/Purpose: The survival of motor neuron (SMN)/gemin proteins are components of a multifunctional protein complex that plays an essential role in RNA metabolism. SMN is…
  • Abstract Number: 1059 • ACR Convergence 2020

    Anti-mitochondrial Autoantibodies Are Associated with Cardiomyopathy, Dysphagia, and Features of More Severe Disease in Adult-onset Myositis

    Sara Sabbagh1, Iago Pinal-Fernandez2, Maria Casal-Dominguez3, Jemima Albayda4, Julie Paik4, Frederick W. Miller2, Lisa G. Rider5, Andrew Mammen3 and Lisa Christopher-Stine4, 1Medical College of Wisconsin, Fox Point, WI, 2National Institutes of Health, Bethesda, MD, 3NIH, Bethesda, MD, 4Johns Hopkins University, Baltimore, MD, 5Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD

    Background/Purpose: We examined the prevalence of anti-mitochondrial autoantibodies (AMA) in adult- and juvenile-onset myositis longitudinal cohorts and investigated phenotypic differences between myositis patients with or…
  • Abstract Number: 0951 • ACR Convergence 2020

    The Comparative Effect of Exposure to Various Risk Factors on the Risk of Hyperuricaemia: Diet Has a Weak Causal Effect

    Ruth Topless1, Tanya Major1, Jose Florez2, Joel Hirschhorn3, Murray Cadzow1, Nicola Dalbeth4, Lisa Stamp5, Phillip Wilcox1, Richard Reynolds6, Joanne Cole2 and Tony Merriman1, 1University of Otago, Dunedin, New Zealand, 2Massachusetts General Hospital, Boston, 3Harvard Medical School, Boston, 4University of Auckland, Auckland, New Zealand, 5University of Otago Christchurch, Christchurch, New Zealand, 6University of Alabama Birmingham, Birmingham

    Background/Purpose: Prevention of hyperuricaemia (HU) is critical to the prevention of gout. Therefore, understanding the causal relationships and relative contributions of various risk factors to…
  • « Previous Page
  • 1
  • …
  • 695
  • 696
  • 697
  • 698
  • 699
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology